ZVRA — Zevra Therapeutics Balance Sheet
0.000.00%
- $657.95m
- $528.87m
- $106.47m
Annual balance sheet for Zevra Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 112 | 82.8 | 67.7 | 69.5 | 191 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.53 | 8.3 | 17.4 | 10.5 | 23.3 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 115 | 92.8 | 86.9 | 86 | 223 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.02 | 1.78 | 1.53 | 1.01 | 1.7 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 133 | 115 | 172 | 178 | 285 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.23 | 12 | 73.7 | 34.1 | 39.3 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 5.82 | 40.2 | 110 | 138 | 130 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 127 | 75.1 | 61.9 | 39.7 | 155 |
| Total Liabilities & Shareholders' Equity | 133 | 115 | 172 | 178 | 285 |
| Total Common Shares Outstanding |